Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Proline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 2/20 | 0.35 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.33 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.33 |
| ▸ | GLI1 | P08151 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | PRCP | P42785 | 1/20 | 0.32 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.32 |
| ▸ | CTSC | P53634 | 1/20 | 0.32 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.32 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.31 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Proline SCHEMBL3100837 | 1.00 | NOS2 (0.35) | NOS2NOS3NOS1DPP4DPP8 | |
| Proline SCHEMBL27413727 | 1.00 | NOS2 (0.35) | NOS2NOS3NOS1DPP4DPP8 | |
| Proline SCHEMBL140699 | 0.94 | NOS2 (0.39) | NOS2NOS3NOS1DPP4DPP8 | |
| Proline SCHEMBL140697 | 0.94 | NOS2 (0.39) | NOS2NOS3NOS1DPP4DPP8 | |
| Proline SCHEMBL285830 | 0.94 | NOS2 (0.39) | NOS2NOS3NOS1DPP4DPP8 | |
| Proline SCHEMBL285829 | 0.94 | NOS2 (0.39) | NOS2NOS3NOS1DPP4DPP8 | |
| Proline SCHEMBL27957063 | 0.94 | NOS2 (0.39) | NOS2NOS3NOS1DPP4DPP8 | |
| Proline SCHEMBL3519300 | 0.94 | NOS2 (0.39) | NOS2NOS3NOS1DPP4DPP8 | |
| Proline SCHEMBL2588291 | 0.94 | NOS2 (0.39) | NOS2NOS3NOS1DPP4DPP8 | |
| Asparagine SCHEMBL4995025 | 0.92 | NOS2 (0.33) | NOS2NOS3NOS1GLI1SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230272071-A1 | MULTIFUNCTIONAL IMMUNOGLOBULIN-FOLD POLYPEPTIDES FROM ALTERNATIVE TRANSLATIONAL INITIATION AND TERMINATION | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2023-08-31 | — | — | US | claimed |
| EP-4188416-A1 | MULTIFUNCTIONAL IMMUNOGLOBULIN-FOLD POLYPEPTIDES FROM ALTERNATIVE TRANSLATIONAL INITIATION AND TERMINATION | Arizona Board of Regents on behalf of the University of Arizona (US) | 2023-06-07 | — | — | EP | claimed |
| WO-2022026358-A1 | MULTIFUNCTIONAL IMMUNOGLOBULIN-FOLD POLYPEPTIDES FROM ALTERNATIVE TRANSLATIONAL INITIATION AND TERMINATION | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2022-02-03 | — | — | WO | claimed |
| EP-2402444-A1 | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof | THE ROCKEFELLER UNIVERSITY (US) | 2012-01-04 | — | — | EP | claimed |
| US-6471956-B1 | DIETETIC AMINO ACID SEQUENCES OR ANOLOGS HAVING IMMUNOGEN SEGMENTS | THE ROCKEFELLER UNIVERSITY | 2002-10-29 | — | — | US | claimed |
| US-6350730-B1 | LEPTIN ANALOGS AS ANTIOBESITY AGENTS; GENETIC ENGINEERING; PRIMERS FOR POLYMERASE CHAIN AMPLIFICATION | THE ROCKEFELLER UNIVERSITY | 2002-02-26 | — | — | US | claimed |
| US-6309853-B1 | NUCLEOTIDE SEQUENCES CODING POLYPEPTIDE ASSOCIATED WITH CONTOLLING BDY WEIGHT; FOR USE IN DIAGNOSIS AND TREATMENT OF EATING DISORDERS | THE ROCKFELLER UNIVERSITY | 2001-10-30 | — | — | US | claimed |
| EP-0777732-A1 | MODULATORS OF BODY WEIGHT, CORRESPONDING NUCLEIC ACIDS AND PROTEINS, AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF | THE ROCKEFELLER UNIVERSITY (US) | 1997-06-11 | — | — | EP | claimed |
| WO-1996005309-A2 | MODULATORS OF BODY WEIGHT, CORRESPONDING NUCLEIC ACIDS AND PROTEINS, AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF | THE ROCKEFELLER UNIVERSITY (US) | 1996-02-22 | — | — | WO | claimed |
| US-20230272071-A1 | MULTIFUNCTIONAL IMMUNOGLOBULIN-FOLD POLYPEPTIDES FROM ALTERNATIVE TRANSLATIONAL INITIATION AND TERMINATION | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2023-08-31 | — | — | US | disclosed |
| EP-4188416-A1 | MULTIFUNCTIONAL IMMUNOGLOBULIN-FOLD POLYPEPTIDES FROM ALTERNATIVE TRANSLATIONAL INITIATION AND TERMINATION | Arizona Board of Regents on behalf of the University of Arizona (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20220211752-A1 | METHIONINE AND CYSTEINE DEPRIVATION DIET AND FORMULATIONS TO INCREASE EFFECTIVENESS OF CANCER THERAPY | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2022-07-07 | — | — | US | disclosed |
| CN-112876578-B | Amphiphilic glucan derivative carrier targeting tumor-associated fibroblasts, and preparation and application of pharmaceutical composition of amphiphilic glucan derivative carrier | 中国药科大学 | 2022-03-18 | — | — | CN | disclosed |
| WO-2022026358-A1 | MULTIFUNCTIONAL IMMUNOGLOBULIN-FOLD POLYPEPTIDES FROM ALTERNATIVE TRANSLATIONAL INITIATION AND TERMINATION | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2022-02-03 | — | — | WO | disclosed |
| EP-1943257-A2 | FIBROBLAST ACTIVATION PROTEIN INHIBITOR COMPOUNDS AND METHODS | Genentech, Inc. (US) | 2008-07-16 | — | — | EP | disclosed |
| US-7399869-B2 | N-blocked peptide proline boronate compounds; hyperproliferative disorders like cancer, neurodegeneration, cardiac hypertrophy, pain, migraine, neurotraumatic disease, cirrhosis, fibromatosis, and rheumatoid arthritis | GENENTECH, INC. (US) | 2008-07-15 | — | — | US | disclosed |
| US-20060276435-A1 | Fibroblast activation protein inhibitor compounds and methods | GENENTECH, INC. (US) | 2006-12-07 | — | — | US | disclosed |
| WO-2006125227-A2 | FIBROBLAST ACTIVATION PROTEIN INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2006-11-23 | — | — | WO | disclosed |
| EP-0777732-A1 | MODULATORS OF BODY WEIGHT, CORRESPONDING NUCLEIC ACIDS AND PROTEINS, AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF | THE ROCKEFELLER UNIVERSITY (US) | 1997-06-11 | — | — | EP | disclosed |
| WO-1996005309-A2 | MODULATORS OF BODY WEIGHT, CORRESPONDING NUCLEIC ACIDS AND PROTEINS, AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF | THE ROCKEFELLER UNIVERSITY (US) | 1996-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276435-A1 | Fibroblast activation protein inhibitor compounds and methods | FAP, FIBP, FGFR1 | NOS2 4245/4885NOS3 4120/4885NOS1 4068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.